T2 Biosystems Stock Is a Buy Amid Breakthrough in COVID-19 Testing
In the last year, T2 Biosystems stock has risen 36 percent. Is TTOO stock a good buy at this price? How's the company's outlook and what can investors expect?
Healthcare
The latest news in the healthcare sector including biotech and telehealth.
When Is Vegan Oat Milk Brand Oatly's IPO Date?
Vegan oat milk brand Oatly may pursue an IPO in 2021, potentially raising $1 billion.
Investing in Janssen Pharmaceuticals Amid COVID-19 Vaccine Push
The FDA approved Janssen Pharmaceuticals’ application to conduct a clinical trial of its COVID vaccine candidate in the Philippines. Is Janssen Pharmaceuticals publicly traded?
How to Get Help With Your Prescriptions With AstraZeneca Patient Assistance
You may not even realize it, but you may be eligible to save money on AstraZeneca prescriptions from the AZ&Me prescription savings program.
Clover Health Is One of the Fastest-Growing Medicare Advantage Companies
Clover Health plans to merge with Social Capital Hedosophia Holdings. Which business is Clover Health into and how does it makes money?
How Does the Pfizer Vaccine Work?
The Pfizer vaccine, though not a live virus, requires extremely cold storage to prevent its genetic material from breaking down.
What Drugs Does AstraZeneca Make?
AstraZeneca is a leading biopharmaceutical company that focuses on developing drugs to treat cancer, heart disease, and COPD. What drugs does the company make?
Is Pfizer’s COVID-19 Vaccine Safe and Effective?
There were a total of six deaths in the late-stage clinical trial for Pfizer’s COVID-19 vaccine. So, is Pfizer’s COVID-19 vaccine safe and effective?
Why Is Peloton So Expensive?
Peloton stationary bikes cost upwards of $2,000 and require a monthly subscription. Why is Peloton so expensive?
The Best Cannabis Stocks for 2021—Here’s What to Buy
Green energy and marijuana stocks have rallied after Biden's election. What are the best cannabis stocks to buy for 2021?
S&P 500’s Top Losses: Why Biogen Declined
Biogen, which is an American multinational biotechnology company, was the S&P 500’s top loss on June 18.
How Vertex’s Revenue and Earnings Surprised in 2Q16
Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.
How Spark Therapeutics Is Positioned in 2018
Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.
Teva Pharmaceutical: Earnings Trends and Recent Developments
Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.Healthcare Farallon Capital adds a new position in Covidien
Ireland-based Covidien is a global healthcare leader that offers innovative medical technology solutions and patient care products to providers.
S&P 500’s Top Gainers: FLIR Systems Rose to Record Highs
FLIR Systems was the S&P 500’s top gainer on July 25. FLIR Systems opened higher on July 25 and rose to record high price levels.
Analyzing AbbVie’s Financial Performance
AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.
How Does UNH’s Valuation Look in October?
UnitedHealth Group is a leading managed healthcare firm in the United States.Consumer Chilton Investment Company buys stake in TransDigm in 4Q13
Chilton started a new position in aerospace engineering company TransDigm Group Inc. (TDG) that accounts for 0.76% of the fund’s fourth quarter portfolio.
Why Chilton starts new position in Wyndham Worldwide
Approximately 63% of Wyndham’s revenues come from fees for providing services referred to as its “fee-for-service” businesses.
Why Pershing Square initiated a position in Platform Specialty Products
Pershing Square disclosed a new position in Platform Specialty Products (PAH) that accounts for 7.58% of Pershing Square’s 1Q14 portfolio.
What Spark Therapeutics’ Valuation Trend Indicates
Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.
Key Drivers of Extra Space’s 2018 Performance
Extra Space (EXR) holds 12% of its total properties in the form of joint ventures and 32% managed for third parties—the largest in the industry.
Where Is Pfizer's COVID-19 Vaccine Being Made?
There's a lot of interest in COVID-19 vaccines. Where is Pfizer's COVID-19 vaccine being made? When will the vaccine be authorized and available?
How to Invest in Lab-Grown Meat Stock
It's official — lab-grown meat has made its way to the market. Eat Just has achieved regulatory approval in Singapore. Can you invest in lab-grown meat stock?
What Happened to Livongo Stock After the Teladoc Merger?
Since Teladoc acquired Livongo, the shares fall under a new umbrella. What happened to Livongo stock after the merger?
When Is the Butterfly Network SPAC IPO Date?
Butterfly Network, a digital health company, is about to go public through a SPAC IPO. When is its IPO date?
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
A Look at Boston Scientific’s Valuation Multiples in September
On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.
How Hologic’s Valuation Stacks Up with Peers
The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.
What’s the Story behind the Pfizer-Medivation Deal?
Medivation’s portfolio complements Pfizer’s existing oncology portfolio that includes solid tumors, hematology, and immunology-oncology.
Boston Scientific Stock Up Today on the Acquisition of Veniti
Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.
Bausch Health Plans to Spin Off Eye Care Business, Shares Surge
Bausch Health plans to spin off its eye care division, Bausch + Lomb, into a standalone public company in a bid to unlock value for shareholders.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta
In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.
REITs 101: Understanding this Investment Vehicle
In this series, we’ll get down to the brass tacks of investing in the REIT sector, the market’s current landscape, and the benefits you can expect from this type of investment.
Increased Life Expectancy Means A Longer Investment Horizon
Increased life expectancy means a longer investment horizon. With life expectancy increasing, young investors should invest in equities aggressively.
Ligand Pharmaceuticals Focuses on Increasing Returns for Shareholders
Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.
Will the Fed Have to Use More Unconventional Measures?
Global monetary policy is unconventional. From an era of lowering interest rates to boost economic growth, central bankers are taking rates into negative territory.
Abbott’s CRM Business Was Flat in 1Q18—What’s Ahead?
In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.
Inside Abiomed’s Profit Margin Expectations for Fiscal 2018
For fiscal 2018 (ended March 31, 2018), Abiomed (ABMD) has projected that its operating margins will be in the range of 22%–24%.
Alnylam Pharmaceuticals: Developing Therapies for Hereditary ATTR Amyloidosis
Alnylam Pharmaceuticals (ALNY) is currently developing three investigational therapies—Patisiran, Revusiran, and ALN-TTRsc02—for the treatment of patients with hereditary ATTR amyloidosis.
What’s behind Biogen Buyout Rumors?
Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.
Varian’s Halcyon Treatment System Sees Emerging Market Demand
Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]
Teva’s Granix Gets FDA Approval for Expanded Indication
Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.
What Do Analysts Recommend for United Therapeutics?
23.1% of analysts gave United Therapeutics (UTHR) a “buy” recommendation while 69.2% of analysts rated the company a “hold.”
Stock Comparison: How Have COP, DVN, OXY, APC, and EOG Fared?
Stock performance In this article, we’ll discuss the year-to-date (YTD) stock performance of ConocoPhillips (COP), Devon Energy (DVN), Occidental Petroleum (OXY), Anadarko Petroleum (APC), and EOG Resources (EOG), which reported the highest revenue among upstream companies in fiscal 2017. Outliers and underperformers The above image shows that ConocoPhillips (COP) is the outlier among peers. YoY […]
GlaxoSmithKline Increases Top Line in 2Q16
GlaxoSmithKline (GSK) reported a 10.9% increase in its top line in its 2Q16 earnings on July 27, 2016. It met Wall Street analysts’ estimates for revenues and EPS.
How to Invest in Global Wide Moat Stocks
The Morningstar Global Wide Moat Focus Index has global exposure, unlike the Morningstar International Moat Index (MOTI).
How Saudi Arabia’s Bond Sale Affects US Treasury Bonds
Saudi Arabia has also been involved in the sale of US Treasuries. The country is the 15th-largest holder of US Treasury bonds in the world.